US Stock Futures Hold Steady Ahead of June Jobs Report as Fed Rate Outlook Remains in Focus 
Samsung to Invest $90 Billion in South Korea to Expand AI Chip, Display, and Battery Production 
Morgan Stanley Names BAE Systems Top European Defence Stock Despite Lower Price Target 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
Japan Signals Surprise Yen Intervention Strategy as BOJ Hawkish Stance Puts FX Traders on Alert 
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan 
Asian Stocks Mixed as South Korea Slides on Profit-Taking, Japan and China Gain on Strong Factory Data 
India Manufacturing PMI Slows in June as Demand Weakens Despite Lower Cost Pressures 
Oil Prices Slip as Iran Talks and Strong Supply Outlook Ease Market Concerns 
TSMC CoWoS Capacity Forecast Raised as Mizuho Sees AI Server CPU Demand Surging Through 2027 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
South Korea Alleges Google Abused Android App Store Dominance, Eyes Major Fine 
U.S. Stocks End Q2 Higher as Strong Jobs Data and AI Rally Lift Wall Street 
US Jobs Report Preview: June Payroll Growth Seen Slowing as Fed Rate Decision Looms 
Turkey Vehicle Sales Fall 11.4% in June as Auto Market Weakens 
Microsoft Reportedly Plans New Job Cuts Across Sales, Consulting, and Xbox 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
Johnson & Johnson acquires Abiomed medical device technology company that develops and manufactures temporary external and implantable mechanical circulatory support devices such as the heart pump. The company invested $16.6 million in the acquisition deal.
Johnson & Johnson revealed its latest investment on Tuesday, Nov. 1, and it was described as its biggest purchase in almost six years. The buyout was a strategic move as the company is looking to bolster its cardiovascular business.
It was noted that the decision was made at a time when Johnson & Johnson was spinning off its consumer health business unit so it could focus on works related to pharmaceuticals and medical devices. The addition of Abiomed to its portfolio through the acquisition deal is expected to scale up its medical device division.
As part of the agreement, the company will pay $380 for each Abiomed share. It will also hand out another $35 per share in cash if the Danvers, Massachusetts-headquartered medical device maker achieves new commercial and clinical milestones, as per CNBC.
Abiomed is known to develop heart pumps and other technology for the treatment of coronary artery disease and heart failure. Its Impella heart pump device is typically used for patients suffering from severe coronary artery disease.
This Johnson & Johnson and Abiomed acquisition agreement is expected to be completed by early next year. Once done, it will help J&J broaden its position as a thriving cardiovascular innovator while also building its medical device segment.
“The addition of Abiomed is an important step in the execution of our strategic priorities and our vision for the new Johnson & Johnson focused on Pharmaceutical and MedTech,” Johnson & Johnson’s chief executive officer, Joaquin Duato, said in a press release.
The CEO added, “We have committed to enhancing our position in MedTech by entering high-growth segments. The addition of Abiomed provides a strategic platform to advance breakthrough treatments in cardiovascular disease and helps more patients around the world while driving value for our shareholders.”
Finally, Johson & Johnson said that Abiomed will be placed under its medical technology unit but that, despite the acquisition, it will continue to operate as a standalone business.
